Tag: sotrovimab or xevudy market growth

Built to provide research that’s more actionable and strategically valuable, The Business Research Company’s 2026 market reports include market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, broader supply chain intelligence, emerging startup tracking, and in-depth product insights.

Sotrovimab Or Xevudy Market Size And Revenue Outlook Through 2030

Historically, this growth stemmed from the emergency authorization of COVID-19 monoclonal antibodies, the high risk of hospitalization observed during the early stages of the pandemic, the swift deployment of antibody therapies, governmental procurement of antiviral treatments, and the expansion of infrastructure for infusion-based treatments.

The projected growth within this period is linked to the advancement of variant-resistant antibody treatments, a heightened focus on preparing for upcoming pandemics, increased capital investment in antiviral biologics, the expansion of outpatient infusion facilities, and the incorporation of monoclonal antibodies into routine medical guidelines.

Key trends anticipated for the forecast period encompass the increasing adoption of monoclonal antibody treatments, a heightened emphasis on addressing viral infections in their initial stages, the broadening availability of targeted antiviral biologics, a greater focus on safeguarding vulnerable patient populations, and accelerated development of therapeutics for pandemic situations.

Get A Free Sample Report With In-Depth Market Insights:

https://thebusinessresearchcompany.com/sample_request?id=46368941&type=smp&name=Sotrovimab%20Or%20Xevudy%20Market%20Report%202026&utm_source=Blogs&utm_medium=Paid&utm_campaign=Oct_PR

Sotrovimab Or Xevudy Market Demand Drivers Opening New Revenue Streams

The increasing occurrence of COVID-19 infections is projected to fuel the expansion of the sotrovimab or xevudy market in the future. COVID-19, an illness resulting from the SARS-CoV-2 virus, disseminates via respiratory droplets and can manifest symptoms ranging from minor fever to critical breathing difficulties. Its dissemination can be mitigated by vaccination and adherence to hygienic practices. The increment in COVID-19 instances is attributable to elements including the emergence of novel variants, diminished immunity, relaxed public health mandates, seasonal indoor assemblies, and inconsistent vaccine distribution. Sotrovimab provides therapy for high-risk COVID-19 sufferers by neutralizing the virus at an early stage, thereby averting severe complications like admission to hospital or fatality. For example, data from the Office for National Statistics, a UK-based government department for official statistics, indicated that in March 2023, approximately 1.9 million individuals in the UK, representing 2.9% of the population, reported having COVID. A significant majority (92%) had contracted COVID-19 more than 12 weeks prior, with 69% enduring symptoms for more than a year and 41% for over two years. Consequently, the expanding occurrence of COVID cases is expected to propel the expansion of the sotrovimab or xevudy market.

Sotrovimab Or Xevudy Market Segment Landscape: Which Areas Lead Development?

The sotrovimab or xevudy market covered in this report is segmented –

1) By Indication: COVID-19 Early Treatment, Post-Exposure Prophylaxis

2) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

3) By End User: Pediatric, Adult, Geriatric

Sotrovimab Or Xevudy Market Industry Leaders And Competitive Landscape

Major companies operating in the sotrovimab or xevudy market are GSK plc, Vir Biotechnology Inc.

View The Full Sotrovimab Or Xevudy Market Report:

https://thebusinessresearchcompany.com/report/sotrovimab-or-xevudy-global-market-report?utm_source=Blogs&utm_medium=Paid&utm_campaign=Oct_PR

Sotrovimab Or Xevudy Market Geographic Landscape: Which Region Leads Industry Growth?

North America was the largest region in the sotrovimab or xevudy market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the sotrovimab or xevudy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Reach Out To Our Team:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Through market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports provide more actionable and strategically valuable research.

Sotrovimab Or Xevudy Market Size, Value And Growth Trends Through 2030

Growth during the historic period was driven by several factors: the emergency authorization granted to monoclonal antibodies for COVID-19, the elevated hospitalization risk observed in the early stages of the pandemic, the swift rollout of antibody-based therapies, government purchases of antiviral drugs, and the broadening of infrastructure dedicated to infusion-based treatments.

The expansion observed during the forecast period is driven by the emergence of antibody therapies effective against different viral variants, heightened emphasis on readiness for pandemics to come, larger financial commitments to antiviral biologic treatments, a broader network of outpatient infusion capabilities, and the incorporation of monoclonal antibodies into established care guidelines. Key developments shaping this period include the growing reliance on monoclonal antibody treatments, an intensified concentration on addressing viral infections at early stages, the widening scope of specialized antiviral biologics, a stronger priority on safeguarding vulnerable populations, and accelerated progress in creating therapeutics designed for pandemic responses.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=20383&type=smp&utm_source=BlogsPR&utm_medium=Paid&utm_campaign=Jul_PR

#Sotrovimab Or Xevudy Market Growth Factors: Which Forces Are Supporting Market Expansion?

The growing number of COVID-19 cases is anticipated to propel the expansion of the sotrovimab (Xevudy) market in the upcoming period. COVID-19, an illness triggered by the SARS-CoV-2 virus, transmits via respiratory droplets and manifests symptoms ranging from mild fever to severe respiratory complications. Preventive measures like vaccines and proper hygiene help curb its dissemination. An upsurge in COVID-19 infections is attributed to emerging variants, waning immunity, relaxed restrictions, seasonal indoor activities, and inconsistent vaccine coverage. By neutralizing the virus early in high-risk patients, sotrovimab prevents severe outcomes such as hospitalization or death. As an example, a March 2023 report from the Office for National Statistics, the UK’s official statistics authority, indicated that around 1.9 million individuals in the UK (2.9% of the population) had reported COVID. Of these, 92% had contracted the virus more than 12 weeks earlier, with 69% enduring symptoms for over a year and 41% for more than two years. Consequently, the escalating prevalence of COVID cases is set to fuel the growth of the sotrovimab or Xevudy market.

Increased healthcare investments are projected to propel the sotrovimab (Xevudy) market forward in the years ahead. Healthcare investments denote the aggregate spending on medical services, including treatments, medications, and hospital care, within a defined timeframe. This spending is on the rise due to an aging population, heightened healthcare demands, breakthroughs in medical technology, and escalating costs for services and pharmaceuticals. Such investments enhance sotrovimab (Xevudy) by funding research and development, scaling up production, and improving access for high-risk patients via collaborations and distribution channels. For instance, a May 2024 report from the Office for National Statistics, a UK governmental body, revealed that total healthcare expenditure grew by 5.6% in nominal terms from 2022 to 2023, a marked acceleration compared to the 0.9% growth recorded in 2022. Hence, the surge in healthcare investments will drive the expansion of the sotrovimab or Xevudy market.

Sotrovimab Or Xevudy Market Segment Outlook: Which Categories Are Expanding The Fastest?

The sotrovimab or xevudy market covered in this report is segmented –

1) By Indication: COVID-19 Early Treatment, Post-Exposure Prophylaxis

2) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

3) By End User: Pediatric, Adult, Geriatric

Sotrovimab Or Xevudy Market Key Companies And Competitive Benchmarking

Major companies operating in the sotrovimab or xevudy market are GSK plc, Vir Biotechnology Inc.

Access The Complete Sotrovimab Or Xevudy Market Report:

https://www.thebusinessresearchcompany.com/report/sotrovimab-or-xevudy-global-market-report?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=Jul_PR

Sotrovimab Or Xevudy Market Geographic Distribution And Regional Opportunities

North America was the largest region in the sotrovimab or xevudy market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the sotrovimab or xevudy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=home_page_test

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports feature advanced enhancements such as market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, delivering more actionable and strategically valuable research.

By 2030, How Much Growth In Market Size Is Expected For The Sotrovimab Or Xevudy Market?

The expansion witnessed in the historical period was primarily due to the urgent approval of COVID-19 monoclonal antibodies, the significant risk of hospitalization in the early stages of the pandemic, the rapid rollout of antibody therapies, governmental acquisition of antiviral treatments, and the growth of infrastructure for infusion-based care.

The expansion anticipated during the forecast period is due to the development of antibody treatments resilient to variants, an increasing emphasis on readiness for future global health crises, heightened funding for biological antiviral agents, the broadening availability of infusion services in outpatient settings, and the incorporation of monoclonal antibody treatments into routine medical procedures.

Key developments expected in the forecast period encompass the escalating application of monoclonal antibody treatments, a heightened concentration on treating viral infections in their initial phases, the proliferation of specific antiviral biological products, an increasing prioritization of safeguarding vulnerable patients, and the accelerated creation of medicines designed for pandemic response.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=20383&type=smp

What Key Growth Drivers Are Influencing The Sotrovimab Or Xevudy Market?

The increasing number of COVID-19 infections is projected to fuel the expansion of the sotrovimab or xevudy market in the future. COVID-19, an illness stemming from the SARS-CoV-2 virus, disseminates via respiratory droplets, leading to symptoms ranging from slight fever to critical respiratory problems. Preventative measures include vaccinations and good hygiene practices. The escalating number of COVID-19 cases can be attributed to elements like novel variants, diminishing immunity, relaxed public health mandates, colder season indoor social events, and inconsistent vaccine distribution. Sotrovimab offers treatment for high-risk COVID-19 patients by neutralizing the virus in its early stages, thereby averting serious consequences such as hospital admission or fatality. For example, data from March 2023, released by the Office for National Statistics, a UK government department for official statistics, indicated that approximately 1.9 million individuals in the UK (2.9% of the population) had COVID at that time. A significant majority (92%) had contracted COVID-19 more than 12 weeks prior, with 69% enduring symptoms for over a year and 41% for over two years. Consequently, the growing incidence of COVID cases is set to propel the growth of the sotrovimab or xevudy market.

What Are The Core Segment Classifications In The Sotrovimab Or Xevudy Market?

The sotrovimab or xevudy market covered in this report is segmented –

1) By Indication: COVID-19 Early Treatment, Post-Exposure Prophylaxis

2) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

3) By End User: Pediatric, Adult, Geriatric

Which Companies Are Influencing The Sotrovimab Or Xevudy Market?

Major companies operating in the sotrovimab or xevudy market are GSK plc, Vir Biotechnology Inc.

Access The Complete Sotrovimab Or Xevudy Market Report:

https://www.thebusinessresearchcompany.com/report/sotrovimab-or-xevudy-global-market-report

Which Region Contributes The Most To The Sotrovimab Or Xevudy Market?

North America was the largest region in the sotrovimab or xevudy market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the sotrovimab or xevudy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

How Does The Market Size Of The Sotrovimab Or Xevudy Market Compare Between 2026 And 2030?

The past period’s expansion was primarily driven by the urgent authorization of COVID-19 monoclonal antibodies, the substantial risk of hospitalization during the early stages of the pandemic, the swift rollout of antibody therapies, the government’s acquisition of antiviral treatments, and the enlargement of infrastructure for infusion-based treatments.

The anticipated expansion during the projected timeframe stems from the advancement of antibody treatments effective against various variants, a heightened emphasis on readiness for forthcoming pandemics, augmented financial commitment to antiviral biological products, the broadened availability of outpatient infusion facilities, and the incorporation of monoclonal antibodies into routine medical guidelines.

Prominent trends for the upcoming period involve the growing application of monoclonal antibody treatments, a sharpened attention on addressing viral infections at their initial stages, the broadening scope of antiviral biologicals designed for specific targets, an increasing prioritization of safeguarding vulnerable patients, and accelerated creation of medicines to combat pandemics.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/sample.aspx?id=20383&type=smp

What Primary Drivers Are Shaping The Sotrovimab Or Xevudy Market?

The increasing number of COVID-19 infections is projected to fuel the expansion of the sotrovimab or xevudy market in the future. COVID-19, an illness stemming from the SARS-CoV-2 virus, disseminates via respiratory droplets, leading to symptoms ranging from slight fever to critical respiratory problems. Preventative measures include vaccinations and good hygiene practices. The escalating number of COVID-19 cases can be attributed to elements like novel variants, diminishing immunity, relaxed public health mandates, colder season indoor social events, and inconsistent vaccine distribution. Sotrovimab offers treatment for high-risk COVID-19 patients by neutralizing the virus in its early stages, thereby averting serious consequences such as hospital admission or fatality. For example, data from March 2023, released by the Office for National Statistics, a UK government department for official statistics, indicated that approximately 1.9 million individuals in the UK (2.9% of the population) had COVID at that time. A significant majority (92%) had contracted COVID-19 more than 12 weeks prior, with 69% enduring symptoms for over a year and 41% for over two years. Consequently, the growing incidence of COVID cases is set to propel the growth of the sotrovimab or xevudy market.

Which Segments Define The Sotrovimab Or Xevudy Market Segment Structure?

The sotrovimab or xevudy market covered in this report is segmented –

1) By Indication: COVID-19 Early Treatment, Post-Exposure Prophylaxis

2) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

3) By End User: Pediatric, Adult, Geriatric

Who Are The Established Players Within The Sotrovimab Or Xevudy Market?

Major companies operating in the sotrovimab or xevudy market are GSK plc, Vir Biotechnology Inc.

Get The Full Sotrovimab Or Xevudy Market Report:

https://www.thebusinessresearchcompany.com/report/sotrovimab-or-xevudy-global-market-report

Which Region Accounts For The Largest Portion Of The Sotrovimab Or Xevudy Market?

North America was the largest region in the sotrovimab or xevudy market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the sotrovimab or xevudy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Sotrovimab Or Xevudy Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/sotrovimab-or-xevudy-global-market-report

Browse Through More Reports Similar to the Global Sotrovimab Or Xevudy Market 2026, By The Business Research Company

Hypermarkets Market Report 2026

https://www.thebusinessresearchcompany.com/report/hypermarkets-global-market-report

Data Lake Market Report 2026

https://www.thebusinessresearchcompany.com/report/data-lake-global-market-report

Market Research Services Market Report 2026

https://www.thebusinessresearchcompany.com/report/market-research-services-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Market Valuation Is Forecasted For The Sotrovimab Or Xevudy Market By 2030 Starting From Its 2026 Size?

Historically, growth was driven by the urgent authorization of COVID-19 monoclonal antibodies, the significant risk of hospitalization during the early phases of the pandemic, the swift deployment of antibody therapies, governmental procurement of antiviral treatments, and the expansion of infrastructure for infusion-based treatments.

The expansion projected for the forecast period is driven by the development of antibody therapies that are resistant to variants, an increasing emphasis on preparedness for future pandemics, a surge in investment directed at antiviral biologics, the broadened availability of outpatient infusion services, and the incorporation of monoclonal antibodies into standard treatment protocols.

Significant trends anticipated for the forecast period encompass the expanding application of monoclonal antibody treatments, a heightened concentration on the early-stage management of viral infections, the growth in targeted antiviral biologics, an increasing priority on safeguarding high-risk patients, and the intensified creation of therapeutics designed for pandemic response.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=20383&type=smp

What Primary Drivers Are Shaping The Development Of The Sotrovimab Or Xevudy Market?

An increasing occurrence of COVID-19 infections is projected to fuel the expansion of the sotrovimab or xevudy market in the future. This illness, caused by the SARS-CoV-2 virus, transmits via respiratory droplets and can manifest symptoms ranging from minor fever to serious breathing difficulties. Its transmission can be curtailed through vaccination and proper hygiene measures. The uptick in COVID-19 infections stems from elements like emerging variants, diminishing immunity, relaxed public health mandates, seasonal indoor assemblies, and inconsistent vaccine distribution. Sotrovimab is administered to high-risk COVID-19 individuals to neutralize the virus early, thereby averting critical results such as hospital admission or fatality. For example, data from March 2023, sourced from a report by the Office for National Statistics, a UK government body for official statistics, indicated that approximately 1.9 million people in the UK (representing 2.9% of the population) had reported COVID as of that month. A significant majority (92%) had contracted COVID-19 more than 12 weeks prior, with 69% enduring symptoms for over a year and 41% for more than two years. Consequently, the escalating incidence of COVID cases is poised to propel the expansion of the sotrovimab or xevudy market.

Which Segment Categories Define The Sotrovimab Or Xevudy Market?

The sotrovimab or xevudy market covered in this report is segmented –

1) By Indication: COVID-19 Early Treatment, Post-Exposure Prophylaxis

2) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

3) By End User: Pediatric, Adult, Geriatric

Who Are The Top Companies Competing In The Sotrovimab Or Xevudy Market?

Major companies operating in the sotrovimab or xevudy market are GSK plc, Vir Biotechnology Inc.

Read the full sotrovimab or xevudy market report here:

https://www.thebusinessresearchcompany.com/report/sotrovimab-or-xevudy-global-market-report

How Does The Sotrovimab Or Xevudy Market Perform Across Major Global Regions?

North America was the largest region in the sotrovimab or xevudy market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the sotrovimab or xevudy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Sotrovimab Or Xevudy Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=20383&type=smp

Browse Through More Reports Similar to the Global Sotrovimab Or Xevudy Market 2026, By The Business Research Company

Hypermarkets Market Report 2026

https://www.thebusinessresearchcompany.com/report/hypermarkets-global-market-report

Data Lake Market Report 2026

https://www.thebusinessresearchcompany.com/report/data-lake-global-market-report

Market Research Services Market Report 2026

https://www.thebusinessresearchcompany.com/report/market-research-services-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Uncover key drivers, emerging technologies, and competitive movements shaping the sotrovimab or xevudy market from 2026–2035 with trusted insights from The Business Research Company

What level of CAGR-driven expansion is anticipated in the Sotrovimab Or Xevudy Market between 2026 and 2030?

The historical growth can be attributed to the emergency approval of COVID-19 monoclonal antibodies, the significant risk of hospitalization during the early stages of the pandemic, the swift rollout of antibody therapies, government acquisition of antiviral treatments, and the expansion of infrastructure for infusion-based treatments.

The growth anticipated for the forecast period can be attributed to the advancement of antibody therapies capable of resisting viral variants, an increasing emphasis on preparing for future pandemics, greater investment in antiviral biologics, the expansion of outpatient infusion services, and the incorporation of monoclonal antibodies into standard medical treatment protocols.

Significant trends during the forecast period include a heightened adoption of monoclonal antibody therapies, an elevated focus on treating viral infections in their early stages, the widening availability of targeted antiviral biologics, a pronounced dedication to safeguarding high-risk patients, and the improved creation of therapeutic agents designed for pandemic response.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=20383&type=smp

What Drivers Are Affecting Demand-Supply Dynamics In The Sotrovimab Or Xevudy Market?

The expanding occurrence of COVID-19 infections is anticipated to propel the sotrovimab or xevudy market in the future. COVID-19, an illness resulting from the SARS-CoV-2 virus, transmits via respiratory droplets and can manifest symptoms ranging from mild fever to serious respiratory problems. Its dissemination can be curbed through vaccinations and good hygiene. The surge in COVID-19 cases is attributed to factors like emerging variants, diminishing immunity, relaxed restrictions, seasonal indoor social events, and inconsistent vaccine distribution. Sotrovimab offers treatment to high-risk COVID-19 individuals by neutralizing the virus at an early stage, thereby averting severe repercussions such as hospital admission or fatality. As an illustration, in March 2023, a report from the Office for National Statistics, a UK-based government department for official statistics, indicated that approximately 1.9 million people in the UK (2.9% of the population) had reported COVID. A significant majority (92%) had experienced COVID-19 more than 12 weeks prior, with 69% enduring symptoms for over a year and 41% for over two years. Consequently, the increasing prevalence of COVID cases will stimulate the expansion of the sotrovimab or xevudy market.

How Is The Sotrovimab Or Xevudy Market Organized Into Various Segments?

The sotrovimab or xevudy market covered in this report is segmented –

1) By Indication: COVID-19 Early Treatment, Post-Exposure Prophylaxis

2) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

3) By End User: Pediatric, Adult, Geriatric

Who Are The Primary Competitors In The Global Sotrovimab Or Xevudy Market?

Major companies operating in the sotrovimab or xevudy market are GSK plc, Vir Biotechnology Inc.

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/sotrovimab-or-xevudy-global-market-report

Which Global Regions Are Shaping The Competitive Landscape Of The Sotrovimab Or Xevudy Market?

North America was the largest region in the sotrovimab or xevudy market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the sotrovimab or xevudy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Sotrovimab Or Xevudy Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=20383&type=smp

Browse Through More Reports Similar to the Global Sotrovimab Or Xevudy Market 2026, By The Business Research Company

Hypermarkets Market Report 2026

https://www.thebusinessresearchcompany.com/report/hypermarkets-global-market-report

Data Lake Market Report 2026

https://www.thebusinessresearchcompany.com/report/data-lake-global-market-report

Market Research Services Market Report 2026

https://www.thebusinessresearchcompany.com/report/market-research-services-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

How Has the Sotrovimab Or Xevudy Market Size Changed, over the years?

The market size for sotrovimab or xevudy has seen a significant surge, marked by XX% growth (HCAGR) in recent times. The said market is predicted to expand from $XX million in 2024 to $XX million in 2025, growing at a compound annual growth rate (CAGR) of XX%. The historic period’s growth can be tied to factors such as the spread of COVID-19, the growing demand for effective monoclonal antibody treatments, enhanced understanding of high-risk patient care, ascending government funding levels, and rising collaborations among pharmaceutical enterprises.

How Much Will the Sotrovimab Or Xevudy Market Be Worth in 2029?

In the coming years, the sotrovimab, also known as xevudy, market is projected to experience an XX (FCAGR) increase. By 2029, it is forecasted to expand to $XX million with a Compound Annual Growth Rate (CAGR) of XX%. The anticipated growth during the forecasted years can be associated with the surging appearance of novel COVID-19 strains, greater emphasis on monoclonal antibody therapies, the extension of healthcare facilities in emerging regions, increased government backing for epidemic readiness, and the expansion of telehealth services for treatment distribution. The major trends expected throughout the forecast period encompass improvements in vaccine production techniques, innovations in drug formulations, the incorporation of telehealth, advancements in technologies for antibody production, and progress in antibody engineering.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=20383&type=smp

Which is the Largest Company in the Sotrovimab Or Xevudy Market?

Major companies operating in the sotrovimab or xevudy market are GSK plc; Vir Biotechnology Inc.

What Are the Main Market Drivers in the Sotrovimab Or Xevudy Industry?

The escalating number of COVID-19 incidents is anticipated to fuel the expansion of the sotrovimab or xevudy market in future. COVID-19, a disease instigated by the SARS-CoV-2 virus, propagates through respiratory droplets and results in symptoms ranging from a mild fever to significant respiratory complications. Its diffusion can be restrained through vaccination and good hygiene practices. The rising trend in COVID-19 cases is due to a variety of factors like emergence of new strains, depreciating immunity, relaxation of restrictions, indoor gatherings during seasons, and uneven distribution of vaccinations. Sotrovimab is utilized to treat high-risk COVID-19 patients by neutralizing the virus at an early stage, averting severe consequences such as hospitalization or death. For instance, a report by the Office for National Statistics, a government department for official statistics in the UK, stated in March 2023, that approximately 1.9 million people in the UK (2.9% of the population) reported having COVID. The majority (92%) had contracted COVID-19 more than 12 weeks prior, with 69% still suffering symptoms for over a year and 41% for more than two years. Hence, the escalating prevalence of COVID cases is set to spur the growth of the sotrovimab or xevudy market.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=20383&type=smp

How Is the Sotrovimab Or Xevudy Market Segments Structured?

The sotrovimab or xevudy market covered in this report is segmented –

1) By Indication: COVID-19 Early Treatment; Post-Exposure Prophylaxis

2) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies

3) By End User: Pediatric; Adult; Geriatric

What Strategic Trends Are Transforming the Sotrovimab Or Xevudy Market?

One noteworthy trend in the sotrovimab or xevudy market involves making strategic investments to enhance research and development, augment production capabilities, and broaden drug availability. These collaborations play a vital role in expediting distribution and ensuring widespread availability, particularly in regions with higher needs. For example, in January 2022, a significant deal was announced by GSK plc, a UK-based pharmaceutical firm, and Vir Biotechnology Inc., a US-based biotechnology firm. They agreed upon additional purchases of sotrovimab, a monoclonal antibody approved for early COVID-19 treatment, with the US government. This deal underlines the continuous demand for effective therapies as the pandemic continues to mutate. Specifically, sotrovimab was developed for adults and adolescents at high risk of severe COVID-19 and provides an essential alternative for those not needing oxygen supplementation. This recent deal reflects a broader strategy by GSK and Vir to maintain sotrovimab’s accessibility despite the emergence of new virus strains.

Access The Full Report Here:

https://www.thebusinessresearchcompany.com/report/sotrovimab-or-xevudy-global-market-report

Which Global Regions Offer the Highest Growth in the Sotrovimab Or Xevudy Market?

North America was the largest region in the sotrovimab or xevudy market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the sotrovimab or xevudy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase The Full Report Today:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=20383

This Report Delivers Insight On:

1. How big is the sotrovimab or xevudy market, and how is it changing globally?

2. Who are the major companies in the sotrovimab or xevudy market, and how are they performing?

3. What are the key opportunities and risks in the sotrovimab or xevudy market right now?

4. Which products or customer segments are growing the most in the sotrovimab or xevudy market?

5. What factors are helping or slowing down the growth of the sotrovimab or xevudy market?

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 2071930708

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Stay ahead with our updated market reports featuring the latest on tariffs, trade flows, and supply chain transformations.

How Has the Sotrovimab Or Xevudy Market Growth Performance Trended Historically, And What Lies Ahead?

The market size of sotrovimab or xevudy has experienced a HCAGR of XX over the recent years. From 2024 to 2025, this market is projected to grow from $XX million to $XX million, with a compound annual growth rate (CAGR) of XX%. The historic growth surge can be correlated to the increased prevalence of COVID-19, heightened demand for efficient monoclonal antibody treatments, elevated awareness regarding care for high-risk patients, augment in government funding, and an increase in partnerships amongst pharmaceutical corporations.

In the upcoming years, we anticipate a XX (FCAGR) increase in the sotrovimab or xevudy market, expected to reach $XX million in 2029 with a compound annual growth rate (CAGR) of XX%. This expected growth during the forecast period is due to various factors like the rising presence of new COVID-19 variants, increased attention to monoclonal antibody cures, development of healthcare accessibility in burgeoning regions, growing governmental aid for preparatory measures for pandemics, and the expansion of telehealth services for treatment provision. Noteworthy trends during this period will be the progress in vaccine production technologies, innovative formulations, telehealth integration, enhancements in antibody generation technologies, and advancement in the field of antibody engineering.

Download a free sample to assess the report’s scope and structure:

https://www.thebusinessresearchcompany.com/sample.aspx?id=20383&type=smp

Which Primay Drivers Are Accelerating Growth in the Sotrovimab Or Xevudy Market?

The escalating number of COVID-19 cases is projected to spur the expansion of the sotrovimab, also known as xevudy, market in future. COVID-19, a disease instigated by the SARS-CoV-2 virus, is transmitted via respiratory droplets and brings about symptoms ranging from a light fever to serious respiratory complications. Its proliferation can be hindered by vaccines and sanitation practices. A growth in COVID-19 instances can be attributed to factors like emerging strains of the virus, diminishing immunity, relaxed safety measures, seasonal indoor congregations, and unequal distribution of vaccines. Sotrovimab is employed to treat high-risk COVID-19 patients by combating the virus at an early stage, thus averting extreme results such as hospitalizations or fatalities. For example, in March 2023, a study released by the Office for National Statistics, a UK governmental department for official statistics, stated that approximately 1.9 million people in the UK (which is 2.9% of the populace) reported having COVID. A majority of them (92%) had contracted COVID-19 more than 12 weeks ago, with 69% suffering from symptoms for over a year and 41% for beyond two years. Therefore, the upswing in the prevalence of COVID cases will fuel the growth of the sotrovimab or xevudy market.

Which Primary Segments of the Sotrovimab Or Xevudy Market Are Driving Growth and Industry Transformations?

The sotrovimab or xevudy market covered in this report is segmented –

1) By Indication: COVID-19 Early Treatment; Post-Exposure Prophylaxis

2) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies

3) By End User: Pediatric; Adult; Geriatric

Request customized data on this market:

https://www.thebusinessresearchcompany.com/customise?id=20383&type=smp

Which Regions Are Key Players in the Growth of the Sotrovimab Or Xevudy Market?

North America was the largest region in the sotrovimab or xevudy market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the sotrovimab or xevudy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Which Emerging Trends that Are Influencing the Sotrovimab Or Xevudy Industry Evolution?

Strategic investments intended to amplify research, enlarge production capabilities, and enhance drug accessibility are defining the sotrovimab or xevudy market’s current trajectory. These initiatives are significant for expediting distribution and ensuring larger scale availability, especially in areas where the need is substantial. In January 2022, for example, UK-based GSK plc collaborated with US-based Vir Biotechnology Inc., to finalize an impactful deal with the United States government to procure additional sotrovimab supplies – a monoclonal antibody permitted for early COVID-19 treatment. This deal affirms the continuous demand for effective cures while the pandemic keeps mutating. Sotrovimab has been specifically developed for adults and young adults who are at high risk of developing severe COVID-19 and is a crucial resource for those who have not yet required oxygen support. This recent collaboration mirrors GSK and Vir’s wider strategy to maintain the accessibility of sotrovimab amidst the advent of new COVID-19 strains.

View the full report here:

https://www.thebusinessresearchcompany.com/report/sotrovimab-or-xevudy-global-market-report

What Parameters Are Used to Define the Sotrovimab Or Xevudy Market?

Sotrovimab (Xevudy) is a monoclonal antibody treatment developed for the management of COVID-19. It is specifically designed to target the SARS-CoV-2 spike protein, preventing the virus from entering and infecting human cells. Sotrovimab is used for treating mild-to-moderate COVID-19 in patients at high risk of progressing to severe illness, offering an effective therapeutic option in early-stage infections.

Purchase the full report and get a swift delivery:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=20383

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

2025 Market Reports Update: Market Size Forecasts to 2034, Key Trends, Leading Players, and Top Regions – Get Ahead of the Competition Today!

What Are the Primary Drivers Supporting the Market Growth of theSotrovimab Or Xevudy Market?

The rise in the prevalence of COVID-19 cases is expected to drive the growth of the sotrovimab or xevudy market going forward. COVID-19 is a disease caused by the SARS-CoV-2 virus, spreading through respiratory droplets and causing symptoms from mild fever to severe respiratory issues. Vaccines and hygiene practices help prevent its spread. COVID-19 cases are increasing due to factors such as new variants, reduced immunity, eased restrictions, seasonal indoor gatherings, and uneven vaccine coverage. Sotrovimab treats high-risk COVID-19 patients by neutralizing the virus early, preventing severe outcomes such as hospitalization or death. For instance, in March 2023, according to a report published by the Office for National Statistics, a UK-based government department for official statistics, as of March 2023, an estimated 1.9 million people in the UK (2.9% of the population) reported COVID. Most (92%) had COVID-19 over 12 weeks earlier, with 69% experiencing symptoms for over a year and 41% for over two years. Therefore, the rise in the prevalence of COVID cases is going to drive the growth of the sotrovimab or xevudy market.

Get Your Free Sample Report Now – Explore Exclusive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=20383&type=smp

#How Does the ProjectedSotrovimab Or Xevudy Market Growth Compare Over the Forecast Period?

The sotrovimab or xevudy market size has XX (HCAGR) in recent years. It will grow from $XX million in 2024 to $XX million in 2025 at a compound annual growth rate (CAGR) of XX%. The growth in the historic period can be attributed to rise in prevalence of COVID-19, the increase in demand for effective monoclonal antibody treatments, growth in awareness of high-risk patient care, rise in government funding, and rise in collaborations between pharmaceutical companies.

The sotrovimab or xevudy market size is expected to see XX (FCAGR) in the next few years. It will grow to $XX million in 2029 at a compound annual growth rate (CAGR) of XX%. The growth in the forecast period can be attributed to rising emergence of new COVID-19 variants, increasing focus on monoclonal antibody therapies, expanding healthcare access in developing regions, rising government support for pandemic preparedness, and growing telehealth services for treatment delivery. Major trends in the forecast period include advancements in vaccine manufacturing technologies, innovation in formulations, integration of telehealth, advancements in antibody production technologies, and advancements in antibody engineering.

You can Directly Purchase the Report Here:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=20383

What Are the Latest Innovations Influencing theSotrovimab Or Xevudy Market?

The key trend in the sotrovimab or xevudy market is the emphasis on strategic investments to boost research and development, expand production capacities, and improve access to the drug. These partnerships are crucial for accelerating distribution and ensuring broader availability, especially in high-need regions. For instance, in January 2022, GSK plc, a UK-based pharmaceutical company, partnered with Vir Biotechnology Inc., a US-based biotechnology company, and announced a significant agreement with the United States government to purchase additional supplies of sotrovimab, a monoclonal antibody authorized for the early treatment of COVID-19. This agreement highlights the ongoing need for effective treatments as the pandemic continues to evolve. Sotrovimab is specifically designed for adults and adolescents at high risk of progressing to severe COVID-19, offering a vital option for those who do not require oxygen supplementation. This recent agreement reflects GSK and Vir’s broader strategy to ensure that sotrovimab remains accessible despite the emergence of new variants of the virus.

Who Are the Major Industry Players Accelerating Growth in theSotrovimab Or Xevudy Market?

Major companies operating in the sotrovimab or xevudy market are GSK plc; Vir Biotechnology Inc.

Order Your Report Now For A Swift Delivery:

https://www.thebusinessresearchcompany.com/report/sotrovimab-or-xevudy-global-market-report

Which Primary Segments of the Sotrovimab Or Xevudy Market Are Driving Growth and Industry Transformations?

The sotrovimab or xevudy market covered in this report is segmented –

1) By Indication: COVID-19 Early Treatment; Post-Exposure Prophylaxis

2) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies

3) By End User: Pediatric; Adult; Geriatric

Gain Exclusive Market Insights—Customize Your Research Report Today for Fast Delivery!

https://www.thebusinessresearchcompany.com/customise?id=20383&type=smp

Which Regions Are Key Players in the Growth of the #What Are the Primary Drivers Supporting the Market Growth of theSotrovimab Or Xevudy Market?# Market?

North America was the largest region in the sotrovimab or xevudy market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the sotrovimab or xevudy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Browse Through More Reports Similar to the Global Sotrovimab Or Xevudy Market 2025, By The Business Research Company:

Antibody Drug Conjugates Global Market Report 2025

https://thebusinessresearchcompany.com/report/antibody-drug-conjugates-global-market-report

Bone Marrow Transplantation Global Market Report 2025

https://thebusinessresearchcompany.com/report/bone-marrow-transplantation-global-market-report

Next-Generation Antibody Therapeutics Global Market Report 2025

https://thebusinessresearchcompany.com/report/next-generation-antibody-therapeutics-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on:

Get 20% off on Global Market Reports until March 31st! Use code FY25SAVE at checkout.

What fueled the previous growth in the sotrovimab or xevudy market?

Over recent years, the sotrovimab or xevudy market has witnessed a HCAGR of XX. The market is projected to expand from $XX million in 2024 to $XX million in 2025 at a Compound Annual Growth Rate (CAGR) of XX%. This growth observed in the historic period is primarily due to the escalating prevalence of COVID-19, heightened demand for efficacious monoclonal antibody treatments, increased awareness around caring for high-risk patients, augmented government funding, as well as a surge in partnerships among pharmaceutical companies.

What will be the sotrovimab or xevudy market size in the future?

The market size for sotrovimab or xevudy is projected to experience a forward compound annual growth rate (FCAGR) of XX% in the following few years, leading it to reach a value of $XX million by 2029. This anticipated economic expansion over the forecast period is likely due to factors like the emergence of new COVID-19 variants, an increased emphasis on monoclonal antibody therapies, enhanced access to healthcare in developing regions, a rise in government support for pandemic readiness, and the expansion of telehealth services for treatment provision. Key trends for the forecast period encompass advancements in vaccine manufacturing technologies, innovative formulations, telehealth integration, improvements in antibody production technologies, and progress in antibody engineering.

Get your sotrovimab or xevudy market report here!

https://www.thebusinessresearchcompany.com/report/sotrovimab-or-xevudy-global-market-report

What main drivers are fueling expansion in the sotrovimab or xevudy market?

The increase in COVID-19 cases is anticipated to stimulate the expansion of the sotrovimab or xevudy market. The disease, triggered by the SARS-CoV-2 virus, propagates through respiratory droplets, causing reactions from mild fever to severe respiratory issues. Its proliferation can be restrained through vaccines and proper hygiene. Elements like new strains, lessened immunity, relaxed restrictions, seasonal indoor gatherings, and unequal vaccine distribution, are causing the rise of COVID-19. The drug sotrovimab is used in treating high-risk COVID-19 patients by deactivating the virus early which prevents severe conditions such as hospitalization or death. For instance, a report by the Office for National Statistics, a UK-based official statistics department, revealed in March 2023 that about 1.9 million individuals in the UK (making up 2.9% of the population) had been diagnosed with COVID. Majority of these patients, around 92%, contracted COVID-19 more than 12 weeks prior. Close to 69% had been coping with symptoms for over a year, with 41% battling them for more than two years. Thus, the escalating prevalence of COVID cases is set to propel the sotrovimab or xevudy market’s growth.

What key areas define the segmentation of the global sotrovimab or xevudy market?

The sotrovimab or xevudy market covered in this report is segmented –

1) By Indication: COVID-19 Early Treatment; Post-Exposure Prophylaxis

2) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies

3) By End User: Pediatric; Adult; Geriatric

Get your free sample now – explore exclusive market insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=20383&type=smp

Who are the dominant players expanding their reach in the sotrovimab or xevudy market?

Major companies operating in the sotrovimab or xevudy market are GSK plc; Vir Biotechnology Inc.

How are evolving market trends shaping sotrovimab or xevudy Strategies?

The main trend evident in the sotrovimab, also known as xevudy, market is the focus on targeted investments to advance research and development, scale up production abilities, and enhance the drug’s accessibility. These alliances play a key role in speeding up distribution and guaranteeing wider availability, particularly in areas of high demand. For instance, in January 2022, GSK plc, a British pharmaceutical firm, forged a partnership with Vir Biotechnology Inc., a biotech company based in the US. This resulted in a significant agreement with the US government for procuring additional sotrovimab supplies, an approved monoclonal antibody for early COVID-19 treatment. The deal underscores the continuous necessity for effective treatments as the pandemic persists. Sotrovimab is particularly purposed for adults and teens at high risk of developing severe COVID-19 and proves to be a crucial treatment alternative for those not needing oxygen supplement. The agreement manifests GSK and Vir’s wider strategy to keep sotrovimab accessible despite the arrival of new virus strains.

Unlock exclusive market insights – purchase your research report now for a swift delivery!

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=20383

Which regions are emerging as leaders in the sotrovimab or xevudy market?

North America was the largest region in the sotrovimab or xevudy market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the sotrovimab or xevudy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Browse Through More Similar Reports By The Business Research Company:

Antibody Drug Conjugates Global Market Report 2025

https://thebusinessresearchcompany.com/report/antibody-drug-conjugates-global-market-report

Bone Marrow Transplantation Global Market Report 2025

https://thebusinessresearchcompany.com/report/bone-marrow-transplantation-global-market-report

Next-Generation Antibody Therapeutics Global Market Report 2025

https://thebusinessresearchcompany.com/report/next-generation-antibody-therapeutics-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on: